Bank of New York Mellon Corp Increases Stake in Cencora, Inc. $COR

Bank of New York Mellon Corp lifted its stake in Cencora, Inc. (NYSE:COR) by 1.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,087,424 shares of the company’s stock after buying an additional 16,076 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.56% of Cencora worth $339,853,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of COR. Acadian Asset Management LLC lifted its position in shares of Cencora by 947.5% during the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the last quarter. Segment Wealth Management LLC bought a new position in shares of Cencora during the 3rd quarter worth approximately $4,830,000. Synergy Asset Management LLC purchased a new stake in Cencora during the third quarter valued at approximately $10,093,000. Exchange Traded Concepts LLC boosted its stake in Cencora by 312.7% in the third quarter. Exchange Traded Concepts LLC now owns 10,458 shares of the company’s stock valued at $3,268,000 after acquiring an additional 7,924 shares in the last quarter. Finally, Central Pacific Bank Trust Division grew its holdings in Cencora by 654.6% in the third quarter. Central Pacific Bank Trust Division now owns 4,188 shares of the company’s stock worth $1,309,000 after purchasing an additional 3,633 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on COR shares. Bank of America lowered their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research report on Monday, January 5th. JPMorgan Chase & Co. raised their price target on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Mizuho upped their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Wells Fargo & Company boosted their target price on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $393.08.

Insider Buying and Selling

In related news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 20,316 shares of company stock valued at $7,151,265 over the last ninety days. Company insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $351.49 on Friday. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The company has a market cap of $68.19 billion, a PE ratio of 44.21, a price-to-earnings-growth ratio of 1.67 and a beta of 0.66. The company’s 50 day moving average is $347.75 and its 200 day moving average is $323.44.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the prior year, the firm earned $3.34 EPS. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.